anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology, microbiology. SUBSTANCE: method involves culturing bacteria Bacillus subtilis on surface of semipermeable membrane placed on solid nutrient medium up to maximal biomass accumulation and transfer of bacteria to spore form followed by mixing bacterial spores with filling agent. Before mixing with filling agent spores were separated from semipermeable membrane. Mixture of sugar and starch at ratio bacterial spore biomass and starch = 1:1 and bacterial spore biomass and sugar = 1:50 (not above) is used as filling agent. EFFECT: simplified technology, enhanced purity of product. 5 cl, 1 tbl
To achieve maximum contraceptive effectiveness, Junel Fe should be taken exactly as directed and at intervals not exceeding 24 hours.

Junel Fe provides a continuous administration regimen consisting of 21 light yellow or pink tablets of Junel and 7 brown non-hormone containing tablets of ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen and do not serve any therapeutic purpose. There is no need for the patient to count days between cycles because there are no “off-tablet days.”

1.
     Sunday-Start Regimen: The patient begins taking the first light yellow or pink tablet from the top row of the dispenser (labeled Sunday) on the first Sunday after menstrual flow begins. When the menstrual flow begins on Sunday, the first light yellow or pink tablet is taken on the same day. The patient takes one light yellow or pink tablet daily for 21 days. The last light yellow or pink tablet in the dispenser will be taken on a Saturday. Upon completion of all 21 light yellow or pink tablets, and without interruption, the patient takes one brown tablet daily for 7 days. Upon completion of this first course of tablets, the patient begins a second course of 28-day tablets, without interruption, the next day (Sunday), starting with the Sunday light yellow or pink tablet in the top row. Adhering to this regimen of one light yellow or pink tablet daily for 21 days, followed without interruption by one brown tablet daily for seven days, the patient will start all subsequent cycles on a Sunday.  
  
  

2.
     Day-1 Start Regimen: The first day of menstrual flow is Day 1. The patient places the self-adhesive day label strip that corresponds to her starting day over the preprinted days on the tablet dispenser. She starts taking one light yellow or pink tablet daily, beginning with the first light yellow or pink tablet in the top row. After the last light yellow or pink tablet (at the end of the third row) has been taken, the patient will then take the brown tablets for a week (7 days). For all subsequent cycles, the patient begins a new 28 tablet regimen on the eighth day after taking her last light yellow or pink tablet, again starting with the first tablet in the top row after placing the appropriate day label strip over the preprinted days on the tablet dispenser. Following this regimen of 21 light yellow or pink tablets and 7 brown tablets, the patient will start all subsequent cycles on the same day of the week as the first course.  
  
Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule.
Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
Antibodies have been modified by chemical conjugation with agents reactive with free amino groups. Among the chemical agents used in connection with the invention are heterobifunctional reagents and biotin. The modified antibodies are also used in the diagnosis and therapy of cancer and other mammalian disease. Diagnostic uses include immunoscintigraphy. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
The invention discloses a formula of medicinal liquor. The medicinal liquor is prepared from the following raw materials by weight: respectively 500-1000g of smallfruit rose roots, fructus rosae laevigatae, raspberry, Chinese holly and bock greenbrier rhizome and liquor which is 0.8-6 times the total weight of the raw materials, wherein the alcoholic strength is not less than 10 degrees. The processing method comprises the following steps: S1, digging fresh roots of smallfruit rose roots, fructus rosae laevigatae, raspberry, Chinese holly and bock greenbrier rhizome, washing and airing for later use; S2, soaking the roots of smallfruit rose roots, fructus rosae laevigatae, raspberry, Chinese holly and bock greenbrier rhizome together in liquor, and then hermetically storing; and S3, soaking for three months and taking out. The processing method can be further improved, and the medicinal liquor is prepared according to the improved method. The medicinal liquor is originated from a secret prescription handed down from ancestors and is soaked by 5-10 shrubs or small magaphanerophytes with thorns. The medicinal liquor has the functions of diminishing swelling and relieving pain, dispelling wind and eliminating dampness, restraining and solidifying and the like and can be used for treating various common diseases such as rheumatic arthralgia, traumatic injury, diarrhea and rectocele.
Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
Methyltestosterone, USP is an androgen. Androgens are derivatives of cyclopentano-perhydrophenanthrene. Endogenous androgens are C-19 steroids with a side chain at C-17, and with two angular methyl groups. Testosterone is the primary endogenous androgen. Fluoxymesterone and methyltestosterone are synthetic derivatives of testosterone.

Methyltestosterone is a white to light yellow crystalline substance that is virtually insoluble in water but soluble in organic solvents. It is stable in air but decomposes in light.

Methyltestosterone structural formula:

Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets contain the following inactive ingredients: acacia, calcium carbonate, carnauba wax, citric acid, colloidal silicon dioxide, di-acetylated monoglycerides, gelatin, lactose, magnesium stearate, methylparaben, microcrystalline cellulose, pharmaceutical glaze, povidone, propylene glycol, propylparaben, shellac glaze, sodium benzoate, sodium bicarbonate, sorbic acid, starch, sucrose, talc, titanium dioxide, tromethamol, FD&C Blue No. 1 Aluminum Lake, and D&C Yellow No. 10 Aluminum Lake.

Esterified Estrogens and Methyltestosterone Tablets also contain: FD&C Yellow No. 6 Aluminum Lake.

Esterified Estrogens and Methyltestosterone Half-Strength Tablets also contain: FD&C Blue No. 2 Aluminum Lake and Iron Oxide Black.
Morphine sulfate extended-release capsules are to be swallowed whole and are not to be chewed, crushed, or dissolved. Taking chewed, crushed, or dissolved morphine sulfate extended-release capsules, USP leads to rapid release and absorption of a potentially fatal dose of morphine.

Morphine sulfate extended-releasecapsules 100 mg ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. This capsule strength may cause fatal respiratory depression when ingested or administered to patients who are not previously exposed to opioids. 

Care should be taken in the prescribing of this capsule strength. Patients should be instructed against use by individuals other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences, including death.
Fatigue is highly prevalent in survivors of diffuse-large B-cell lymphoma (DLBCL). Fatigue has been linked to chronic inflammation, and diets high in antioxidant nutrients (diet rich in fruit, vegetables, whole grains, and omega-3 fatty acid-rich foods) have been associated with lesser prevalence and severity of fatigue. Studies are needed, however, to test if antioxidant-rich diets could improve fatigue in this patient population. This fatigue-reducing diet (FRD) was shown to improve fatigue and sleep in breast cancer survivors compared to regular diet. This FRD diet aligns with the standard of care dietary recommendations for cancer survivors promoted by the American Cancer Society (ACS) . The purpose of this small preliminary study is to gather preliminary data to support a large randomized controlled trial. This study will provide nutritional counseling to 10 adult patients (18 years or older) with DLBCL who have completed their upfront chemotherapy treatment and remained in remission for 2 years prior to enrollment. The study will employ individualized dietary counseling, provided by a registered dietitian (RD), by phone or video teleconferencing. Phone counseling will be weekly for the first month, and then biweekly for the next two months, for a total of 8 phone sessions. Counseling sessions take \~15-30 minutes. Dietary intake will be assessed using an electronic food frequency questionnaire at baseline and 3 months. Fatigue will be assessed using an online survey at baseline and 3 months. The purpose of the study to ascertain the percentage of patients who are able to complete all the study questionnaires and visits and adhere to the fatigue reduction diet. Data obtained from this preliminary study would be used to support a well-powered future randomized trial of FRD vs regular diet in survivors of DLBCL.
BACKGROUND: Traditional methods for treating diabetic wounds are limited in effectiveness because of their long healing times, the risk of immune rejection, and susceptibility to infection. Suppressing neutrophil extracellular traps (NETs) is an effective strategy for reducing persistent inflammation in diabetic wounds. Although disulfiram (DSF) can inhibit the significant increase of NETs in diabetic wounds, oral DSF suffers from rapid and harmful metabolism in the liver. To address these challenges, we developed a nanomedicine formulation in which DSF was incorporated into the hydrogel.
METHODS: In this study, we developed a DSF-laden sodium alginate hydrogel wound dressing, DEP@SA, and characterized its composition, properties, and performance. We examined the effects of DEP@SA on inflammatory phase-related markers such as NETs and their pathway proteins, inflammatory factors, and macrophage phenotypes in a high-glucose environment in vivo and in vitro. In addition, the effects of DEP@SA on tissue regenerative capacity such as epidermal proliferative migration and angiogenesis, were also assessed.
RESULTS: The results showed that by utilizing extracellular vesicles as a drug delivery system, we effectively mitigated the degradation of DSF via direct contact with aqueous solutions and ensured the stability of DSF@SA, which could then be applied to diabetic wounds. The inflammatory phase-related indicators revealed that DSF@SA effectively reduced inflammation levels, decreased NETs formation, suppressed the Caspase-1/GSDMD pathway in neutrophils, and promoted the polarization of M2 macrophages. Moreover, the hydrogel accelerated wound healing by promoting angiogenesis and re-epithelialization, thereby shortening the diabetic wound healing time.
CONCLUSIONS: This study confirmed that the DSF@SA composite dressing has the potential to enhance diabetic wound repair and offers a novel approach for drug reutilization.
Extracellular neuraminidase (NANAase) is produced by the microorganism Arthrobacter sialophilum sp. nov. The enzyme is induced from this microorganism by a variety of glycoproteins. The preferred enzyme inducer is a hot water extract of edible bird's nest which has been mildly acid-treated. The microorganisms, after aerobic growth in complete medium of relatively simple composition, are harvested, washed, salt-shocked, and induced in mineral salts solution which leads to facile enzyme induction. The produced NANAase is purified by ammonium sulfate fractionation, DEAE cellulose chromatography, gel filtration and ultrafiltration. The enzyme can further be readily crystallized from concentrated solutions. Disc gel electrophoresis at both acidic and basic pH's showed a major protein band. The predominant protein contained NANAase activity. The NANAase has an apparent molecular weight of 87,000 daltons. The purified enzyme has a pH optimum of 5-6, an apparent Km of 2.08 mg/ml for Collocalia mucoid and 3.3 x 10-3 M for N-acetylneuraminlactose and is insensitive to Ca++ ions and EDTA. Linkage specificity studies using N-acetylneuraminlactose and colominic acid indicated that the NANAase hydrolyzes ( alpha ,  2-3), ( alpha , 2-6) or ( alpha , 2-8) linkages. The above-identified microorganism produces about 5 mg of NANAase/liter of induction medium and is an excellent source for the preparation of relatively large quantities of homogeneous NANAase.
Headaches caused by trauma are called post-traumatic headaches (PTH). The Center for Disease Control estimates that between 1.4 and 1.8 million civilians in the US sustain a traumatic brain injury (TBI) each year. The objectives of the study will be evaluated in a civilian population which has sustained a mild Traumatic Brain Injury (mTBI). Research has found that the total cost due to headache in the US workforce is $20 billion per year, most of which is in the form of reduce productivity while at work. For patients with TBI who are already struggling with cognitive and health challenges in an effort to be productive, it seems reasonable to suspect that chronic PTH may slow rehabilitation efforts and successful re-entry into the work force and societal responsibility. Results from this study have the potential to contribute to recommendations for treatment of chronic PTH.
The solution deals with vaccine, which contains dissolvable antigens of cysticercus of the tape-worm insolubilized on liposomal particles with the adjuvant effect and potentiated by levisamole as immunomodulator. Its production method starts from the mixture of lecithin and cholesterol. This mixture is solved in chloroform and it evaporates under the decreased pressure. Protein antigen, levamisole in the buffered physiological solution, is added to the evaporation residue, it is mixed, stabilized and sonicated two to three times when simultaneously being cooled. After three hours of stabilization, the vaccine is prepared for use or conversation for the possible storage. The conservation can be carried out chemically e.g. by glutaraldehyde in the concentration of maximal 0.5 percent by weight or lyophilisation and freezing. The vaccine has no side effects in vivo and its hypodermic application is easy and safe. The prophylactic agent can be used with small farm animals, e.g. rabbits.
BACKGROUND AND OBJECTIVES: In most neurosurgical centers, irrigation is an essential part of the surgical procedure for chronic subdural hematoma (CSDH). However, it is unknown whether the volume of irrigation fluid affects the risk of CSDH recurrence. This study aimed to investigate a potential association between the volume of irrigation fluid used during burr hole evacuation of CSDH and the risk of CSDH recurrence.
METHODS: This study is a subanalysis of 2 randomized trials (Drain Time & Drain Time 2) designed to investigate the effect of drainage duration on the recurrence of CSDH. Intraoperative irrigation volume was measured, and patients were followed for 90 days for recurrent CSDH.
RESULTS: A total of 525 patients with CSDH were included. There was no significant difference in the volume of irrigation fluid used between patients with recurrence (mean = 938 mL, SD = ±552) and without recurrence (mean = 852 mL, SD = ±454) ( P -value = .15). Patients with recurrent CSDH had larger primary CSDH volumes (mean = 134 cm 3 , SD = ±69) than patients without recurrence (mean = 119 cm 3 , SD = ±58) ( P = .04). Multiple logistic regression analysis revealed no association between irrigation volume and recurrence, also when stratified for hematoma size.
CONCLUSION: There was no significant association between irrigation volume and recurrent CSDH within 90 days in patients undergoing burr hole surgery for CSDH.
This study aims to determine the effect of immersion bathing and showering on comfort levels and physiological parameters of newborns in neonatal intensive care units.

This is a randomized controlled experimental study. The sample consisted of a total of 69 newborns who were born at the 37th gestational week and above, were referred to the neonatal intensive care unit of a training and research hospital, and met the study inclusion criteria. Study groups were determined through randomization by throwing a dice (immersion bathing group:35, showering group:34). Environmental variables were kept the same for both groups. Physiological parameters (respiration, high heart rate, oxygen saturation, body temperature) and comfort levels of newborns in both groups were compared before, just after and 15 minutes after the bath. Their comfort levels were measured using the Newborn Comfort Behavior Scale (NCBS).
The recommended daily maintenance dosage of pirfenidone tablets is 801 mg three times daily for a total of 2,403 mg/day. Doses should be taken with food at the same time each day.

Upon initiation of treatment, titrate to the full dosage of 2,403 mg/day over a 14-day period as follows: 

Table 1. Dosage Titration for pirfenidone tablets in Patients with IPF

Dosages above 2,403 mg/day are not recommended for any patient. Patients should not take 2 doses at the same time to make up for a missed dose. Patients should not take more than 3 doses per day.
Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove \& Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
CGM data will be "unblinded", with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary.
Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
Participants in the intervention group were asked to exercise three times per week while performing four basic bodyweight exercises in a circuit manner for 12 weeks while supervised online via the Microsoft TEAMs platform. Participants were eased into the program by completing 120 minutes of exercise in week one, 150 minutes in week two, and 180 minutes in the following weeks. Participants were supervised 3X/week for the first four weeks, then 2X/week for the next four weeks and 1X/week for the remaining four weeks. At each session, participants performed the four prescribed exercises (squats, tricep dips, lunges, and push-ups) for 45 seconds each, then switched immediately (15 seconds) to the next exercise followed by one minute of rest at the end of each circuit. Following this exercise program, men living with obesity were able to reach moderate intensity.
Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m\^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
Participants will experience a modified version of NUSMart with the multicomponent intervention enabled. This intervention consists of a subset of the combined interventions tested in Aim 1 namely, 1. Food labels (with the summary of healthiness of shopping baskets \& targets), 2. Ordering and 3. Within Group Healthier Substitution.
Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
The present invention addresses the problem of providing a method that enables more accurate suggestions for improving both the health and beauty conditions of a user.　A second acquisition unit 121 acquires the user's intestinal bacteria data. A score determination unit 122 determines a score that indicates the health level of the intestinal environment of the user on the basis of the intestinal bacteria data. A type determination unit 123 determines the type to which the user's intestinal flora applies, among a plurality of intestinal bacteria flora types, on the basis of the intestinal bacteria data. An information unit 125 informs suggestions for improving the user's health condition to the user on the basis of the user's score and type. The problem is solved thereby.
Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.